GUTS
Fractyl Health Inc.

1,454
Mkt Cap
$261.75M
Volume
1.32M
52W High
$3.03
52W Low
$0.825
PE Ratio
-0.84
GUTS Fundamentals
Price
$1.83
Prev Close
$1.91
Open
$1.86
50D MA
$1.84
Beta
1.12
Avg. Volume
4.23M
EPS (Annual)
-$1.44
P/B
-79.45
Rev/Employee
$869.16
Loading...
Loading...
News
all
press releases
Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Expands By 24.0%
Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 11,893,654 shares, a growth...
MarketBeat·18h ago
News Placeholder
More News
News Placeholder
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat reports. One...
MarketBeat·9d ago
News Placeholder
Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat reports...
MarketBeat·1mo ago
News Placeholder
Fractyl Health (NASDAQ:GUTS) CEO Acquires $19,998.72 in Stock
Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the stock in a transaction on Thursday, December 4th. The stock was acquired at an average cost of...
MarketBeat·1mo ago
News Placeholder
Insider Buying: Fractyl Health (NASDAQ:GUTS) CEO Buys 10,416 Shares of Stock
Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the firm's stock in a transaction that occurred on Thursday, December 4th. The shares were acquired...
MarketBeat·1mo ago
News Placeholder
Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs
Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy.read more...
Benzinga·2mo ago
News Placeholder
Fractyl's Revita Procedure Shows 6-Month Post-GLP-1 Weight Stability In REVEAL-1 Study
(RTTNews) - Fractyl Health (GUTS) reported new six-month data from its open-label REVEAL-1 cohort, showing that people with obesity who stopped GLP-1 drugs maintained both weight and glycemic control...
Nasdaq News: Markets·2mo ago
News Placeholder
Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have received an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, MarketBeat...
MarketBeat·2mo ago
News Placeholder
Canaccord Genuity Group Issues Positive Forecast for Fractyl Health (NASDAQ:GUTS) Stock Price
Canaccord Genuity Group raised their target price on Fractyl Health from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat·2mo ago
News Placeholder
Brokers Set Expectations for Fractyl Health FY2025 Earnings
Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Analysts at HC Wainwright lifted their FY2025 earnings per share estimates for Fractyl Health in a report issued on Thursday, November 13th. HC...
MarketBeat·2mo ago
<
1
2
...
>

Latest GUTS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.